0001103021-22-000074.txt : 20220322
0001103021-22-000074.hdr.sgml : 20220322
20220322171809
ACCESSION NUMBER: 0001103021-22-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220322
FILED AS OF DATE: 20220322
DATE AS OF CHANGE: 20220322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vollins James
CENTRAL INDEX KEY: 0001757833
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 22760707
MAIL ADDRESS:
STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL
STREET 2: 4131 PARK LAKE AVE SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
wf-form4_164798387074964.xml
FORM 4
X0306
4
2022-03-22
1
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001757833
Vollins James
C/O BIODELIVERY SCIENCES INTL, INC.
4131 PARKLAKE AVE. SUITE 225
RALEIGH
NC
27612
0
1
0
0
See Remarks
Restricted Stock Units
0.0
2022-03-22
4
D
0
91401
0
D
Common Stock
91401.0
0
D
Stock Options (right to buy)
3.46
2022-03-22
4
D
0
29826
0
D
Common Stock
29826.0
0
D
Stock Options (right to buy)
3.9
2022-03-22
4
D
0
43334
0
D
Common Stock
43334.0
0
D
Stock Options (right to buy)
3.84
2022-03-22
4
D
0
269244
0
D
Common Stock
269244.0
0
D
Stock Options (right to buy)
3.03
2022-03-22
4
D
0
82508
0
D
Common Stock
82508.0
0
D
Stock Options (right to buy)
3.66
2022-03-22
4
D
0
282055
0
D
Common Stock
282055.0
0
D
Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
General Counsel, Chief Compliance Officer & Corporate Secretary
/s/ James Vollins
2022-03-22